Trial Profile
A Phase IIb Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms RAMTAS
- 20 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2021 Interim results (n=80) of safety analysis from patients enrolled in arm A and arm B presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 13 Nov 2020 Planned number of patients changed from 144 to 426.